一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0900 | 0.1100 | -18.18 | 0.0500 | | 每股净资产（元） | 7.76 | 8.44 | -8.06 | 8.18 | | 每股公积金(元) | 4.39 | 4.4 | -0.23 | 4.36 | | 每股未分配利润(元) | 2.58 | 3.05 | -15.41 | 2.44 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.59 | 1.66 | -4.22 | 1.43 | | 净利润(亿元) | 0.33 | 0.41 | -19.51 | 0.17 | | 净资产收益率(%) | 1.09 | 1.25 | -12.8 | 0.55 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 14895.52万股，累计占流通股比： 40.81 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.2700 | 0.2000 | 35 | 0.2500 | | 每股净资产（元） | 9.58 | 9.09 | 5.39 | 8.53 | | 每股公积金(元) | 3.74 | 3.66 | 2.19 | 3.64 | | 每股未分配利润(元) | 4.33 | 3.91 | 10.74 | 3.38 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.42 | 0.42 | 0 | 0.35 | | 净利润(亿元) | 0.11 | 0.08 | 37.5 | 0.1 | | 净资产收益率(%) | 2.87 | 2.20 | 30.45 | 3.00 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | | --- | --- | - ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0984 | -0.0025 | -3836 | 0.0093 | | 每股净资产（元） | 2.39 | 2.85 | -16.14 | 2.88 | | 每股公积金(元) | 3.47 | 3.47 | 0 | 3.47 | | 每股未分配利润(元) | -2.45 | -1.99 | -23.12 | -1.96 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 10.12 | 13.09 | -22.69 | 12.22 | | 净利润(亿元) | -1.07 | -0.03 | -3466.67 | 0.1 | | 净资产收益率(%) | -3.98 | -0.09 | -4322.22 | 0.32 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 67475.71万股， ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0031 | -0.0058 | 46.55 | -0.0040 | | 每股净资产（元） | 0.3 | 0.38 | -21.05 | 0.62 | | 每股公积金(元) | 0.49 | 0.49 | 0 | 0.49 | | 每股未分配利润(元) | -1.03 | -0.97 | -6.19 | -0.73 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.98 | 0.87 | 12.64 | 0.45 | | 净利润(亿元) | -0.08 | -0.16 | 50 | -0.12 | | 净资产收益率(%) | -1.00 | -1.53 | 34.64 | -0.71 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 68104.01万股，累计占流通股比： 28 ...

前十大流通股东累计持有： 47139万股，累计占流通股比： 46.87%，较上期变化： 2031.02万股。 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0157 | 0.0005 | 3040 | 0.0169 | | 每股净资产（元） | 2.42 | 2.38 | 1.68 | 2.17 | | 每股公积金(元) | 0.07 | 0.05 | 40 | 0.03 | | 每股未分配利润(元) | 1.13 | 1.12 | 0.89 | 0.96 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.13 | 3.49 | -38.97 | 4.13 | | 净利润(亿元) | 0.16 | 0 | 0 | 0.18 | | 净资产收益率(%) | 0.64 | 0.02 | 3100 | 0.78 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0174 | -0.0641 | 72.85 | 0.0095 | | 每股净资产（元） | 2.27 | 2.2 | 3.18 | 2.18 | | 每股公积金(元) | 1.5 | 1.5 | 0 | 1.43 | | 每股未分配利润(元) | -0.25 | -0.30 | 16.67 | -0.26 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.87 | 0.71 | 22.54 | 0.67 | | 净利润(亿元) | -0.07 | -0.26 | 73.08 | 0.04 | | 净资产收益率(%) | -0.77 | -2.87 | 73.17 | 0.44 | | 持有数量(万股) 名称 | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.1300 | -0.0700 | -85.71 | -0.0800 | | 每股净资产（元） | 12.21 | 12.19 | 0.16 | 11.72 | | 每股公积金(元) | 0.44 | 0.43 | 2.33 | 0.43 | | 每股未分配利润(元) | 10.15 | 10.15 | 0 | 9.68 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 7.88 | 9.29 | -15.18 | 10.22 | | 净利润(亿元) | -0.7 | -0.36 | -94.44 | -0.44 | | 净资产收益率(%) | -1.03 | -0.53 | -94.34 | -0.68 | 本次公司不分配不转赠。 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 34579.62万股，累计占流通股比： 6 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002484 证券简称：江海股份 公告编号：2025-028 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □适用 √不适用 □是 √否 ■ （二） 非经常性损益项目和金额 √适用 □不适用 单位：元 ■ 其他符合非经常性损益定义的损益项目的具体情况 □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 公司不存在将《公开发行证券的公司信息披露解释性公告 ...

Core Insights - SouthState (SSB) reported a revenue of $630.64 million for the quarter ended March 2025, marking a 51.8% increase year-over-year and exceeding the Zacks Consensus Estimate by 2.35% [1] - The earnings per share (EPS) for the quarter was $2.15, up from $1.58 in the same quarter last year, resulting in an EPS surprise of 50.35% compared to the consensus estimate of $1.43 [1] Financial Metrics - Net Interest Margin (Non-Tax Equivalent) was reported at 3.8%, slightly above the estimated 3.6% [4] - The Efficiency Ratio stood at 61%, higher than the average estimate of 57% [4] - Total nonperforming assets were $280.44 million, exceeding the estimated $251.43 million [4] - Net charge-offs as a percentage of average loans (annualized) were 0.4%, compared to the estimated 0.1% [4] - Average Balance of Total interest-earning assets was $57.50 billion, below the estimated $58.46 billion [4] - Net Interest Income was reported at $544.55 million, surpassing the average estimate of $516.19 million [4] - Total Noninterest Income was $86.09 million, slightly below the estimated $88.27 million [4] - Net interest income, tax equivalent (Non-GAAP) was $545.33 million, exceeding the average estimate of $528.97 million [4] Stock Performance - SouthState's shares have returned -5.6% over the past month, compared to a -5.1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Merit Medical reported revenue of $355.35 million for the quarter ended March 2025, reflecting a year-over-year increase of 9.8% and exceeding the Zacks Consensus Estimate of $352.33 million by 0.86% [1] - The company's EPS for the quarter was $0.86, up from $0.77 in the same quarter last year, resulting in an EPS surprise of 14.67% compared to the consensus estimate of $0.75 [1] Financial Performance Metrics - U.S. sales reached $213.56 million, surpassing the average estimate of $208.66 million by analysts, marking a year-over-year increase of 14.8% [4] - International sales were reported at $141.79 million, slightly below the estimated $143.33 million, with a year-over-year growth of 3.2% [4] - Revenue from Cardiovascular-Peripheral Intervention was $137.28 million, below the average estimate of $141.95 million, showing a 2% increase year-over-year [4] - Cardiovascular-Cardiac Intervention revenue was $99.74 million, exceeding the estimated $98.79 million, with a 10% year-over-year increase [4] - Endoscopy revenue was reported at $16.64 million, below the average estimate of $17.89 million, but reflecting a significant year-over-year increase of 64.2% [4] - Cardiovascular-OEM revenue reached $53.75 million, surpassing the average estimate of $43.84 million, with a year-over-year increase of 36.9% [4] - Total Cardiovascular revenue was $338.71 million, slightly above the estimated $334.45 million, representing an 8.1% year-over-year increase [4] - Revenue from Cardiovascular-Custom Procedural Solutions was $47.94 million, below the average estimate of $49.74 million, indicating a year-over-year decline of 1.8% [4] Stock Performance - Over the past month, Merit Medical's shares have returned -9.6%, compared to a -5.1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]